abstract |
Disclosed are N-hydroxy-3-(4-{3-phenyl-s-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds of formula (I) as histone deacetylase inhibitors (HDACs) for the treatment of diseases linked to the deregulation of histone deacetylases activity such as cancer. |